Respiratory function and respiratory complications in spinal cord injury: protocol for a prospective, multicentre cohort study in high-income countries by Raab, A.M. et al.
1Raab AM, et al. BMJ Open 2020;10:e038204. doi:10.1136/bmjopen-2020-038204
Open access 
Respiratory function and respiratory 
complications in spinal cord injury: 
protocol for a prospective, multicentre 
cohort study in high- income countries
Anja M Raab   ,1 Martin W G Brinkhof   ,2 David J Berlowitz   ,3,4 
Karin Postma   ,5 David Gobets   ,6 Sven Hirschfeld,7 Maria T E Hopman   ,8 
Burkhart Huber,9 Margret Hund- Georgiadis   ,10 Xavier Jordan   ,11 
Martin Schubert,12 Renate Wildburger   ,13 Gabi Mueller   1
To cite: Raab AM, 
Brinkhof MWG, Berlowitz DJ, 
et al.  Respiratory function 
and respiratory complications 
in spinal cord injury: protocol 
for a prospective, multicentre 
cohort study in high- income 
countries. BMJ Open 
2020;10:e038204. doi:10.1136/
bmjopen-2020-038204
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
038204).
AMR and MWGB contributed 
equally.
Received 11 March 2020
Revised 16 July 2020
Accepted 05 October 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Gabi Mueller;  
 gabi. mueller@ paraplegie. ch
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction Pneumonia is one of the leading 
complications and causes of death after a spinal cord injury 
(SCI). After a cervical or thoracic lesion, impairment of the 
respiratory muscles decreases respiratory function, which 
increases the risk of respiratory complications. Pneumonia 
substantially reduces patient’s quality of life, may prolong 
inpatient rehabilitation time, increase healthcare costs 
or at worse, lead to early death. Respiratory function and 
coughing can be improved through various interventions 
after SCI, but the available evidence as to which aspect 
of respiratory care should be optimised is inconclusive. 
Furthermore, ability of respiratory function parameters 
to predict pneumonia risk is insufficiently established. 
This paper details the protocol for a large- scale, 
multicentre research project that aims to evaluate the 
ability of parameters of respiratory function to predict and 
understand variation in inpatient risk of pneumonia in SCI.
Methods and analysis RESCOM, a prospective cohort 
study, began recruitment in October 2016 across 10 SCI 
rehabilitation centres from Australia, Austria, Germany, the 
Netherlands and Switzerland. Inpatients with acute SCI, with 
complete or incomplete cervical or thoracic lesions, 18 years 
or older and not/no more dependent on 24- hour mechanical 
ventilation within the first 3 months after injury are eligible 
for inclusion. The target sample size is 500 participants. The 
primary outcome is an occurrence of pneumonia; secondary 
outcomes include pneumonia- related mortality and quality 
of life. We will use the longitudinal data for prognostic 
models on inpatient pneumonia risk factors.
Ethics and dissemination The study has been reviewed 
and approved by all local ethics committees of all 
participating centres. Study results will be disseminated to 
the scientific community through peer- reviewed journals 
and conference presentations, to the SCI community, 
other stakeholders and via social media, newsletters and 
engagement activities.
Trial registration details  ClinicalTrials. gov 
NCT02891096.
INTRODUCTION
Pneumonia is a leading complication and 
cause of death after a spinal cord injury (SCI), 
even in high- income countries.1 2 In newly 
injured patients, pneumonia may substan-
tially complicate and lengthen the period of 
first rehabilitation, while community dwelling 
persons living with SCI are commonly re- hos-
pitalised for pneumonia over extended 
periods that frequently involve intensive 
care.3 4
Contemporary healthcare policy and 
patient management aim to improve health- 
related Quality of Life (QoL) and life expec-
tancy in the SCI community as well as to 
reduce infection- related healthcare costs. 
Reducing the incidence of pneumonia is, 
Strengths and limitations of this study
 ► RESCOM is the first multinational study to pro-
spectively evaluate predictors of pneumonia from a 
representative sample of persons with spinal cord 
injury (SCI) receiving inpatient rehabilitation in a 
high- income setting.
 ► The RESCOM cohort will enrol 500 persons with SCI 
to develop generalisable prognostic models as well 
as to validate causal risk factors, specifically im-
paired respiratory function, of pneumonia risk.
 ► Because respiratory function following SCI may be 
improved through respiratory muscle training, study 
results may inform and improve current clinical 
practice and patient management through the better 
targeting of interventions.
 ► Generalisability of the study with respect to pneu-
monia risk is limited to patients with less than 
24 hours of mechanical ventilation within the first 
3 months after injury, because respiratory function 
cannot be measured using standard techniques in 
those who are intubated.
 ► This study will provide insight whether the improve-
ment of respiratory muscle strength and respiratory 
function represent promising targets for intervention 
to reduce pneumonia risk following SCI.
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therefore, a major objective. Critical to this goal is that 
(1) persons with an elevated risk of pneumonia can be 
identified early (prediction), (2) modifiable risk factors 
are known (causality) and readily measurable and (3) 
effective interventions targeting key risk factors are 
established. Unfortunately, however, the contemporary 
evidence base regarding risk groups and modifiable risk 
factors of pneumonia in SCI, and subsequent effective 
intervention strategies, remain scant.5–8 Most existing 
studies evaluating between- person differences in risk 
of pulmonary complications assessed non- modifiable 
factors only: demographics (sex and age), injury severity 
(level and completeness) or spinal shock severity.5 6 8 Only 
one recent study investigated modifiable risk factors for 
pneumonia, that is, steroid administration, which may be 
helpful to maintain muscle mass and strength but may 
also cause other relevant side effects.9
Impairment of respiratory function represents the most 
promising target for clinically relevant research on pneu-
monia in SCI, as these measures are directly linked to the 
neurological impairment and appear to be modifiable 
through targeted respiratory training.10–12 Respiratory 
muscles below the level of injury may become paralysed or 
impaired13 and respiratory function is compromised with 
higher levels of injury causing greater impairment.10 14 
Cough impairment is also considered critically important, 
as insufficient removal of airway secretions may result in 
the development of mucus plugging and complications 
such as atelectasis or pneumonia.15 16 Effective coughing 
comprises an inspiration, compression and expulsion 
phase. Cough impairment following SCI may affect each 
phase due to the weakening of inspiratory and expira-
tory muscle function, which may decrease the maximum 
volume of expelled air by restricting both the maximum 
inspiratory volume prior to contraction as well as a reduc-
tion in the amount able to be expelled.15 17 The limited 
evidence in SCI suggests that inspiratory (using maximal 
inspiratory muscle pressure, PImax) rather than expiratory 
function (maximal expiratory muscle pressure, PEmax) is 
the prime determinant of cough capacity (peak flow), 
particularly in patients with a motor- complete cervical 
SCI.18 Postma et al found that impaired pulmonary func-
tion may increase respiratory infections at 1 year after SCI, 
but their study did incorporate that respiratory muscle 
strengthening and respiratory complications were incom-
pletely assessed.7
To the best of our knowledge, there is currently 
no comprehensive database available for the further 
development of generalisable prognostic models, nor to 
improve causal inference of pneumonia risk in light of 
impairment in respiratory function. The multicentre and 
multinational cohort study, RESpiratory COMplications 
(RESCOM), aims to establish such an evidence base in 
SCI. We believe RESCOM will thereby improve clinical 
practice through better targeting of interventions during 
the inpatient setting in high- income countries.
METHODS AND ANALYSES
Design and setting
RESCOM is a prospective international, multicentre 
cohort study in high- income countries. Data collec-
tion commenced in October 2016 across 10 specialised 
rehabilitation centres for SCI from Austria (2 centres), 
Australia (1 centre), Germany (1 centre), the Nether-
lands (2 centres) and Switzerland (4 centres), and is still 
ongoing.
Study population
Newly injured persons who are aged 18 years or older, 
admitted for inpatient rehabilitation in the participating 
centres, with complete or incomplete lesions (grades 
A–D on the American Spinal Injury Association (ASIA) 
Impairment Scale (AIS))19 and cervical or thoracic lesion 
levels (right and left motor levels between C1 and T12) 
are eligible for study participation. Persons with severe 
pre- existing scoliosis, progressive neurological diseases, 
24- hour mechanical ventilation dependency until more 
than 3 months after injury or severe mental disorders are 
excluded.
Sample size
For the analysis of pneumonia risk we estimated, over 
a conservative range of pneumonia event probabili-
ties from 0.1 to 0.2, the minimal sample size needed to 
detect a plausible HR (effect size of interest) of 1.7 or 
more for inspiratory muscle strength (principal predictor 
variable).20 Using a conventional power of 0.8 and signif-
icance level of 0.05, this analysis indicated a sample size 
of 500 as adequate for the purpose of the present study.
Procedures
The measurement schedule of RESCOM includes up to 
four measurement time- points (T1–T4) during the inpa-
tient rehabilitation period (figure 1). Following start of 
rehabilitation, newly injured patients are contacted for 
Figure 1 Time frames for measurements (time- ponts: T1–T4) during inpatient rehabilitation. T1–T3 time- windows with days 
post injury (dpi) are shown by grey bars and T4 by the grey arrow above.
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recruitment at about 4 weeks (T1) or at 12 weeks (T2) if 
the first 6 weeks or more weeks following injury were spend 
in the intensive care unit (ICU) or in a general hospital 
for acute care. Subsequent assessments are planned at 24 
weeks (T3) and at discharge to the community (T4). The 
T4 time- point may precede and replace T2 and/or T3 in 
patients with a shorter length of inpatient rehabilitation 
stay. Temporal start and length of inpatient stay for reha-
bilitation varies with injury severity, general health status 
of patients and between countries and clinics. Conse-
quently, between two and four measurement time- points 
are anticipated across patients, with those with more 
severe lesions and the longest length of stay providing 
more time points. In the four Swiss centres, RESCOM is 
run as a ‘nested project’ of the Swiss SCI (SwiSCI) cohort 
study ( www. swisci. ch).20 The temporal schedule of data 
collection of RESCOM is aligned to that of SwiSCI and 
the relevant data for RESCOM will be extracted from 
the SwiSCI database additionally to RESCOM- specific 
measurements and questionnaires.
Quality control
Each of the participating centres has one or two respon-
sible study nurses. Before the start of recruitment, a study 
nurse meeting in the Swiss Paraplegic Centre Nottwil was 
performed to train all study nurses for the procedures 
and the assessments of the study. A study manual has been 
established to give an overview of the procedures and all 
assessed variables. A frequently asked question sheet is 
available in the study- specific database (secuTrial, iAS, 
Berlin, Germany) with all relevant questions the study 
nurses asked during data collection. For quality control 
of data assessment, regular central (database secuTrial) 
and one local monitoring visit in each of the participating 
centres are performed. The coordinating study centre 
supports one central study coordinator who is responsible 
for central and local monitoring as well as for support of 
the local study nurses for questions concerning patient 
inclusion, data collection and entry into the database.
Parameters assessed
Primary outcome
The occurrence of pneumonia is the primary outcome of 
RESCOM, observed continuously during the whole risk 
period of interest from time of injury until the end of 
inpatient rehabilitation. Medical records of inpatients are 
screened for diagnosis of pneumonia, including records 
from the acute care phase before admission to the reha-
bilitation centre. Pneumonia is classified by type and 
cause, and the date of onset and duration of each event 
is recorded. Pneumonia is clinically diagnosed using the 
criteria described in the pneumonia flow diagram as 
endorsed by the Centers for Disease Control and Preven-
tion.21 Mortality is defined as pneumonia related, if pneu-
monia was clinically recorded as the initiating cause of 
events leading to death. Other causes of death are simi-
larly classified.
Participant characteristics
All participant characteristics are obtained from medical 
records. Basic characteristics that are collected at T1 
include gender, age, height, cause of SCI (traumatic or 
non- traumatic) and smoking history. Parameters that 
may temporally vary, including body weight, motor lesion 
level and AIS, medication, frequency of defecation as 
well as medical complications, are assessed on all avail-
able measurement time- points. At T4, the actual smoking 
status and International Classification of Diseases (ICD-
10) coded comorbidities are recorded additionally.
Additional parameters
Additional parameters assessed at all measurement time- 
points, that is, up to four times per participant (further 
details on these measurements and questionnaires are 
given below):
 ► Measurement of respiratory muscle strength and lung 
function.
 ► International Spinal Cord Society (ISCoS) Pulmonary 
Function Data Set.22
 ► Quantiative questionnaire on physical exercise 
training.
 ► Quantitative questionnaire on respiratory therapy 
and respiratory muscle training.
 ► Bogenhausener Dysphagia Score (BODS).
 ► ISCoS QoL Questionnaire.23
 ► COVID-19 assessment form.
Measurement of respiratory function
Measurement of respiratory function consists of respira-
tory muscle strength (PImax and PEmax) and lung function 
with forced vital capacity (FVC), forced expiratory volume 
in 1 s (FEV1), peak expiratory flow (PEF) and peak cough 
flow (PCF). All measurements are performed at the same 
day according to the American Thoracic Society/Euro-
pean Respiratory Society guidelines24 in a sitting position 
either in the participant’s own wheelchair or on a chair 
in which participants are able to walk. To derive a reliable 
estimate of the highest value for each parameter, each 
measurement is repeated until the three highest values 
of a given parameter are within a 20% range. The highest 
value of each parameter is retained for further analysis.25
Measurement of respiratory muscle strength and lung 
function have been harmonised across the 10 centres 
using identical equipment. PImax and PEmax are measured 
using a hand- held respiratory pressure metre (Micro 
RPM, Micro Medical, Hoechberg, Germany). The PImax 
measurement is derived from residual volume and PEmax 
from total lung capacity, against the occluded one- way 
valve of the respiratory pressure metre with the pressure 
maintained for at least 1 s. To derive the maximum pres-
sure over a 1- second period, the patient is instructed to 
maintain inspiratory and expiratory pressure for at least 
1.5 s.26 Abdominal binders are removed prior to any 
measurement of respiratory function.27
The FVC is the total volume of air the participant is 
able to exhale after a maximal inspiration. The FEV1 is 
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the total volume of air that has been exhaled at the end of 
the first second of maximal forced expiration. PEF is the 
maximum flow of air achieved during the maximum expi-
ratory flow manoeuvre.28 During the PCF manoeuvre, the 
maximum flow of air is measured by having the participant 
cough as forcefully as possible through a peak flow metre. 
Participants breathe through a mouthpiece while wearing 
a nose clip. Across study centres, lung function parame-
ters are measured accordingly, but using three different 
brands of portable spirometer, including Micro Loop 
(Care Fusion, Basingstoke, the UK; all Swiss, Dutch and 
German centres), EasyOne Spirometer (Niche Medical, 
Melbourne, Australia; Australian centre), Masterscreen 
PFT Pro (Care Fusion, Hoechberg, Germany; one 
Austrian centre) and Vitalograph (Ennis, Ireland; one 
Austrian centre).
ISCoS Pulmonary Function Data Set
The ISCoS Pulmonary Function Data Set22 consists of 
questions on pulmonary complications (asthma, chronic 
obstructive pulmonary disease, sleep apnoea and others) 
before and after SCI, smoking history, current utilisation 
of pulmonary assistance and lung function measurement.
Questionnaires on physical exercise and respiratory muscle 
training as well as on respiratory therapy
The questionnaires on individual respiratory muscle 
training, regular physical exercise and therapy are kept as 
simple as possible. Only quantitative or yes/no questions 
on physical activities performed during the last 7 days 
are asked. Physical activity, duration of sport activities as 
well as number of physiotherapy sessions per week are 
recorded. Respiratory therapies such as mobilisation of 
secretions, manual blowing or air stacking and insuffla-
tion/exsufflation are assessed on a yes/no basis and if yes, 
whether with or without manual cough assistance. Respi-
ratory muscle training is assessed separately for inspi-
ratory and expiratory muscle strength training as well 
as respiratory muscle endurance training (ie, isocapnic 
hyperpnoea). In case of training, the name of the device, 
the number of training sessions per week, the number of 
repetitions per session as well as the resistance is noted.
Bogenhausener Dysphagia Score
Dysphagia is assessed using the BODS, which consist of 
two scales, each with a score from 1 to 8, resulting in a 
sum score of 2–16. The first scale quantifies swallowing 
of saliva and whether the patient has a tracheal cannula. 
For patients with tracheal cannula, the degree of blocking 
is quantified as fully, partly or mainly not blocked. The 
second scale quantifies problems with oral ingestion, 
including 4 of the 8 scores for parenteral nutrition. The 
BODS is assessed by a speech therapist or a physiothera-
pist, in close coordination with the RESCOM study nurse.
ISCoS Quality of Life questionnaire
QoL is evaluated using the ISCoS QoL questionnaire.23 
This measurement instrument accepts a multifaceted 
concept and includes three questions that capture general 
QoL (overall well- being), rating of physical health and 
satisfaction with psychological health.
COVID-19 assessment form
At the start of the COVID-19 pandemic (March 2020), 
we implemented an additional form into the study data-
base and instructed all study nurses of each participating 
centre to additionally fill in this form for the actually 
included and future patients. Since COVID-19 infections 
are often leading to severe pneumonia and probably also 
death, we identified this as a potential confounder of our 
study results and, therefore, have to include this infection 
into our analysis. The COVID-19 form includes informa-
tion on diagnosis, date of diagnosis, symptoms and death 
due to COVID-19.
Database secuTrial
To enable secure capture and management of RESCOM 
data, the professional and web- browser- based database 
system secuTrial is used. SecuTrial fulfils the minimal 
requirements for data storage and management indi-
cated in the good clinical practice guidelines and also 
supports the central monitoring of data collection across 
all participating centres. Database set- up, personal 
accounts with pre- defined roles for all study collaborators 
as well as support, data export and archiving are provided 
by a study- independent database manager from the study- 
centre in Nottwil, Switzerland.
Methods of minimising bias
Study participants receive an introduction for the study 
procedure by the local study nurse skilled in the manage-
ment of persons with SCI and trained for all study specific 
tasks. A standardised study protocol was defined to mini-
mise attrition bias.
The coding of the participants is conducted by the study 
nurses of each site in order to keep the data management 
and the biostatistician blinded (de- identified at source). 
The coding list remains with the study nurses of each site 
for the whole duration of the study and archiving period. 
Thus, coding is conducted without any influence of the 
principal investigator, the data manager or biostatistician. 
The study investigators strive for complete separation of 
the persons involved in the steps of enrolment and data 
collection from those involved in the data management 
and analysis.
All assessments are conducted and entered into the 
study database by the trained study nurse(s) of each 
participating centre.
Patient and public involvement
No patients or public have been directly involved in the 
planning or conduct of this study. Study results will be 
disseminated to the scientific community through peer- 
reviewed journals and conference presentations, to the 
SCI community, other stakeholders and via social media, 
newsletters and engagement activities.
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Statistics
Statistical analysis will involve basic descriptive statis-
tics and multivariable regression analyses that take into 
account the longitudinal and multilevel structure of the 
data. A global overview of the multivariable data analysis 
plan for investigating the association between respiratory 
function and pneumonia is given in figure 2. To evaluate 
variation in pneumonia risk, time- to- event analysis tech-
niques (eg, flexible parametric survival modelling) will be 
employed, taking date of injury as the starting point of 
the risk period. Regression models targeting causal infer-
ence will make use of time- updated information for all 
variables in accordance with the repeated measurement 
schedule of RESCOM, while controlling for between- 
person and between- centre sources of variance using 
random and fixed effects. The exposure ‘respiratory func-
tion’ will be operationalised using parameters of respira-
tory muscle strength and parameters of lung function, 
as a latent construct within generalised latent variable 
modelling or as individual parameters in selected anal-
ysis as required.29 Critical confounders that have been 
defined using evidence from the literature and expert 
opinion of RESCOM collaborators include age, lesion 
severity, time since injury (structurally captured in time- 
to- event modelling), artificial ventilation and medication. 
Models targeting prognosis of pneumonia during first 
rehabilitation will only include parameters of respiratory 
function that have been collected at baseline.30 31
ETHICS AND DISSEMINATION
Full ethical approval for this project has been obtained by 
all local ethics committees of all participating centres. We 
certify that all applicable institutional and governmental 
regulations concerning the ethical use of data of human 
volunteers are followed during the course of this research.
Potential protocol modifications and amendments 
will be submitted to the ethical committees for approval. 
This project has been registered with  ClinicalTrials. gov 
NCT02891096 and regular study updates are presented 
on Research Gate (https://www. researchgate. net/ 
project/ RESCOM- RESpiratory- COMplications- after- 
Spinal- Cord- Injury).
All participants gave written or witnessed verbal consent, 
if upper limb function is too impaired for a participant to 
sign, prior to entering the study.
The study results will be disseminated through publica-
tion in scientific journals, presentation at relevant confer-
ences, directly to the participants and clinicians as well 
as on social media and in newsletters. The dissemination 
aims to provide clinicians with reliable prognostic factors 
to identify persons who are at heightened risk of pneu-
monia and thus, to effectively reduce pneumonia risk and 
pneumonia- related hospitalisations.
STRENGTH AND LIMITATIONS
RESCOM is the first prospective, international study 
that reports modifiable predictors of pneumonia from a 
representative sample of persons with SCI during inpa-
tient rehabilitation. Its comprehensive evidence base 
facilitates the systematic evaluation of the discriminatory 
power of respiratory function parameters for pneumonia 
risk in high- income countries.
The RESCOM study is effective in recruiting a repre-
sentative sample of inpatients with a motor complete or 
incomplete SCI in Austria, Australia, Germany, the Neth-
erlands and Switzerland. The anticipated minimal sample 
Figure 2 Global scheme of the planned data analysis investigating the dynamic association between respiratory function and 
pneumonia. In regression modelling, all variables will be time- updated in accordance with the repeated measurement schedule 
of RESpiratory COMplications and controlling for between- person and between- centre sources of variance. Respiratory 
function is operationalised using parameters of respiratory muscle strength and parameters of lung function. 4300.7802.430. P
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size of 500 should provide project sufficient statistical 
power to answer the key hypothesis that respiratory func-
tion, and PImax in particular, is a strong prognostic param-
eter that quantifies clinical pneumonia risk in SCI. The 
longitudinal, international design of this project is consid-
ered a further strength; participants can be observed 
during the whole period of inpatient rehabilitation in 
different countries. Various factors like a central web- 
based database, a study nurse meeting, a comprehensive 
study manual and regular monitoring were implemented 
to ensure the standardisation of the measurements and 
data and thus to keep quality of the project in the 10 
centres as high as possible.
For data collection, we used the International SCI Core 
Data Set,32 33 the International SCI QoL Basic Data Set23 
and the International SCI Pulmonary Function Data 
Set,22 which are developed to provide global data stan-
dards for SCI clinical research. The advantage of using 
these standardised data sets is to increase the data quality 
and to facilitate data sharing.
Potential limitations include the observational nature 
of the project which limits causal inference even within a 
prospective study design. Although the RESCOM sample 
reflects the composition of the source population quite 
well, we cannot exclude potential selection bias and, 
therefore, the results of the RESCOM project may not be 
transferable to all persons with SCI. There is a risk that 
the study inclusion and exclusion criteria may miss those 
patients with a potential high risk of pneumonia because 
those with more severe lesions or more complications 
may not consent to participate in an observational study 
that may not directly increase their outcome. Similarly, 
patients with a very long stay in the intensive care unit (eg, 
due to polytrauma) or a very late admission to the rehabil-
itation unit may miss T2 and, therefore, no more qualify 
for study participation. Those patients with 24 hours of 
mechanical ventilation are excluded since respiratory 
function cannot be measured and also those with other 
languages than used in our study centres are excluded. 
Another limitation of this project is that we do not have a 
follow- up period after the participants complete inpatient 
rehabilitation.
In summary, using discriminatory parameters of respi-
ratory function, clinicians may identify persons with SCI 
who are at heightened risk of developing pneumonia 
during inpatient rehabilitation. Thus, interventions can 
be targeted at these persons to reduce pneumonia risk. 
The RESCOM study is well positioned to determine prog-
nostic parameters of respiratory function for pneumonia 
risk in SCI.
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